237 related articles for article (PubMed ID: 23900151)
1. Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: I. HMGB1 suppression by DHMEQ prevents early islet graft damage.
Kuraya D; Watanabe M; Koshizuka Y; Ogura M; Yoshida T; Asahi Y; Kamachi H; Nakamura T; Harashima H; Ozaki M; Umezawa K; Matsushita M; Yamashita K; Todo S
Transplantation; 2013 Sep; 96(5):445-53. PubMed ID: 23900151
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune responses and permits long-term islet allograft acceptance.
Watanabe M; Yamashita K; Kamachi H; Kuraya D; Koshizuka Y; Shibasaki S; Asahi Y; Ono H; Emoto S; Ogura M; Yoshida T; Ozaki M; Umezawa K; Matsushita M; Todo S
Transplantation; 2013 Sep; 96(5):454-62. PubMed ID: 23860082
[TBL] [Abstract][Full Text] [Related]
3. Donor pretreatment with DHMEQ improves islet transplantation.
Takahashi T; Matsumoto S; Matsushita M; Kamachi H; Tsuruga Y; Kasai H; Watanabe M; Ozaki M; Furukawa H; Umezawa K; Todo S
J Surg Res; 2010 Sep; 163(1):e23-34. PubMed ID: 20638688
[TBL] [Abstract][Full Text] [Related]
4. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Ueki S; Yamashita K; Aoyagi T; Haga S; Suzuki T; Itoh T; Taniguchi M; Shimamura T; Furukawa H; Ozaki M; Umezawa K; Todo S
Transplantation; 2006 Dec; 82(12):1720-7. PubMed ID: 17198266
[TBL] [Abstract][Full Text] [Related]
5. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Suzuki E; Umezawa K
Biomed Pharmacother; 2006 Nov; 60(9):578-86. PubMed ID: 16978829
[TBL] [Abstract][Full Text] [Related]
7. A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice.
Funakoshi T; Yamashita K; Ichikawa N; Fukai M; Suzuki T; Goto R; Oura T; Kobayashi N; Katsurada T; Ichihara S; Ozaki M; Umezawa K; Todo S
J Crohns Colitis; 2012 Mar; 6(2):215-25. PubMed ID: 22325176
[TBL] [Abstract][Full Text] [Related]
8. A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets.
Watanabe M; Lundgren T; Saito Y; Cerami A; Brines M; Östenson CG; Kumagai-Braesch M
Transplantation; 2016 Mar; 100(3):554-62. PubMed ID: 26683514
[TBL] [Abstract][Full Text] [Related]
9. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.
Wakamatsu K; Nanki T; Miyasaka N; Umezawa K; Kubota T
Arthritis Res Ther; 2005; 7(6):R1348-59. PubMed ID: 16277688
[TBL] [Abstract][Full Text] [Related]
10. Dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-kappaB inhibitor, inhibits allergic inflammation and airway remodelling in murine models of asthma.
Shimizu K; Konno S; Ozaki M; Umezawa K; Yamashita K; Todo S; Nishimura M
Clin Exp Allergy; 2012 Aug; 42(8):1273-81. PubMed ID: 22805475
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory effect of nuclear factor-κB inhibition by dehydroxymethylepoxyquinomicin in combination with donor-specific blood transfusion.
Goto R; Yamashita K; Aoyagi T; Ueki S; Uno M; Oura T; Kobayashi N; Igarashi R; Shibasaki S; Wakayama K; Hirokata G; Shibata T; Zaitsu M; Umezawa K; Ozaki M; Todo S
Transplantation; 2012 Apr; 93(8):777-86. PubMed ID: 22357176
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
13. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
Nagai N; Izumi-Nagai K; Oike Y; Koto T; Satofuka S; Ozawa Y; Yamashiro K; Inoue M; Tsubota K; Umezawa K; Ishida S
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4342-50. PubMed ID: 17724226
[TBL] [Abstract][Full Text] [Related]
14. Nuclear factor-κB activation inhibitor attenuates ischemia reperfusion injury and inhibits Hmgb1 expression.
Shi Z; Lian A; Zhang F
Inflamm Res; 2014 Nov; 63(11):919-25. PubMed ID: 25209109
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF-kappaB inhibitor.
Takatsuna H; Morita S; Nagatsu T; Sawada M; Umezawa K
Biomed Pharmacother; 2005 Jul; 59(6):318-22. PubMed ID: 15932789
[TBL] [Abstract][Full Text] [Related]
16. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic potential of dehydroxymethylepoxyquinomicin for NF-κB suppression via reactive oxygen species and unfolded protein response.
Nakajima S; Kato H; Gu L; Takahashi S; Johno H; Umezawa K; Kitamura M
J Immunol; 2013 Jun; 190(12):6559-69. PubMed ID: 23690471
[TBL] [Abstract][Full Text] [Related]
18. Low-dose rapamycin unmasks the protective potential of targeting intragraft NF-κB for islet transplants.
Zammit NW; Tan BM; Walters SN; Liuwantara D; Villanueva JE; Malle EK; Grey ST
Cell Transplant; 2013; 22(12):2355-66. PubMed ID: 23127588
[TBL] [Abstract][Full Text] [Related]
19. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
Nishimura D; Ishikawa H; Matsumoto K; Shibata H; Motoyoshi Y; Fukuta M; Kawashimo H; Goto T; Taura N; Ichikawa T; Hamasaki K; Nakao K; Umezawa K; Eguchi K
Int J Oncol; 2006 Sep; 29(3):713-9. PubMed ID: 16865289
[TBL] [Abstract][Full Text] [Related]
20. Prevention of high-mobility group box 1-mediated early loss of transplanted mouse islets in the liver by antithrombin III.
Kojima D; Mera T; Nishinakamura H; Itoh T; Ogata T; Matsuoka N; Kodama S; Yasunami Y
Transplantation; 2012 May; 93(10):983-8. PubMed ID: 22446936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
